Share This Page
Drug Price Trends for REPAGLINIDE
✉ Email this page to a colleague
Average Pharmacy Cost for REPAGLINIDE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| REPAGLINIDE 0.5 MG TABLET | 62135-0946-90 | 0.08060 | EACH | 2026-03-18 |
| REPAGLINIDE 0.5 MG TABLET | 57237-0157-01 | 0.08060 | EACH | 2026-03-18 |
| REPAGLINIDE 2 MG TABLET | 72603-0812-01 | 0.08586 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Repaglinide
Repaglinide, a meglitinide analog, is an oral hypoglycemic agent used to manage type 2 diabetes. It stimulates insulin release from the pancreas by binding to the ATP-dependent potassium channels on beta cells. Approved by the FDA in 1997 under the brand name Prandin (Novo Nordisk), repaglinide competes with other insulin secretagogues such as sulfonylureas and newer agents like GLP-1 receptor agonists.
Market Size and Segmentation
Global Diabetes Market
The global type 2 diabetes therapeutics market was valued at USD 50.9 billion in 2022[1]. Growth drivers include increasing prevalence of diabetes, expanding geriatric population, and technological innovation. The insulin and oral hypoglycemic segment constitutes approximately 65% of this market.
Repaglinide Specifics
Repaglinide's sales are a subset within the oral hypoglycemic segment, which totaled USD 16 billion in 2022[2]. Although marketed since 1997, repaglinide's market share has declined with the advent of newer agents such as DPP-4 inhibitors and SGLT2 inhibitors.
Geographic Market Penetration
- North America: Dominates with over 50% of sales, driven by high diabetes prevalence and insurance coverage.
- Europe: Accounts for approximately 25%, with strong generic penetration.
- Asia-Pacific: Rapid growth due to increasing diabetes prevalence; expected to grow at a CAGR of 8% through 2030[3].
Competitive Landscape
| Company | Drug Name | Market Share (2022) | Key Features | Patent Status | Pricing (per 30 tablets) |
|---|---|---|---|---|---|
| Novo Nordisk | Prandin | Approximately 35% | Fast-acting, taken before meals | Patent expired in 2014 | USD 70-90 |
| Sun Pharmaceutical | Generic repaglinide | Approximate 50% of generic market | Cost-efficient | Patent expired | USD 10-20 |
| Others | Various generics | Remaining market share | Price competition | Patent expired | USD 5-15 |
Patent Status: Original patents expired in 2014, leading to widespread generic manufacturing.
Generic competition has driven prices down from branded levels, with some markets seeing tablets priced as low as USD 0.50 per dose.
Pricing Trends and Projections
Historical Price Dynamics
- 2010: Average retail price for branded repaglinide was USD 3-4 per tablet.
- 2014: Patent expiry prompted price reduction to USD 0.50–1.00 per tablet.
- 2020: Prices stabilized around USD 0.30–0.80, depending on market and manufacturer.
Projected Price Trends (2023-2028)
- Generics: Prices are expected to decrease marginally as production scales increase, with prices stabilizing around USD 0.20 per tablet.
- Branded: Limited renewal of patents and increased generics will diminish branded market prices to near-generic levels.
Factors Influencing Price Trends
- Patent expiration and generics proliferation.
- Regulatory policies promoting generic substitution.
- Shifts toward combination therapies reducing demand for standalone repaglinide.
- Market entry of newer, more effective, and often better-tolerated agents such as SGLT2 inhibitors.
Market Dynamics and Future Outlook
- Patient Population: The growing prevalence of type 2 diabetes necessitates affordable treatment options, maintaining demand for low-cost agents like repaglinide.
- Therapeutic Shifts: Despite being cost-effective, repaglinide's utilization declined due to concerns over hypoglycemia and weight gain relative to SGLT2 inhibitors and GLP-1 receptor agonists.
- Regulatory Trends: Governments and insurers favor generics, promoting lower pricing and wider access.
Potential for Growth
Investments in combination therapies, especially those pairing repaglinide with metformin, may preserve niche markets. However, competition from newer classes and clinical preferences toward agents with cardiovascular benefits limit substantial market expansion.
Key Takeaways
- Repaglinide’s global market is shrinking, mainly due to generics and emerging therapies.
- Price projections indicate stabilization around USD 0.20–0.50 per tablet due to high generic competition.
- North America and Europe emphasize cost-efficiency, fostering generic dominance.
- Asia-Pacific shows significant growth potential owing to diabetes prevalence and pricing sensitivity.
- Future growth relies on clinical positioning against newer agents and potential combination drug formulations.
FAQs
1. Will repaglinide regain market share against newer diabetes drugs?
Unlikely, as newer therapies offer additional benefits such as weight loss and cardiovascular risk reduction, sidelining repaglinide mainly as a cost-effective option.
2. How do patent expirations affect repaglinide pricing?
Patent expiration increases generic entry, drives prices downward, and shifts market share toward cost-efficient generics.
3. What are main challenges for repaglinide manufacturers?
Competition from cheaper generics, evolving clinical guidelines favoring other drug classes, and the necessity to innovate combination therapies.
4. What is the outlook for repaglinide in emerging markets?
Strong, as affordability remains critical; prices are expected to stay low, supporting continued use.
5. Are there any upcoming regulatory changes impacting repaglinide?
No significant regulatory hurdles are expected in major markets. Focus remains on approval and reimbursement policies favoring generics.
References
[1] Markets and Markets. Diabetes Therapeutics Market, 2022.
[2] IQVIA. Global Prescription Drug Market Analysis, 2022.
[3] Mordor Intelligence. Asia-Pacific Diabetes Market Forecast, 2022-2030.
More… ↓
